Astellas Pharma (JP:4503) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Japan’s Ministry of Health, Labour and Welfare has approved Astellas Pharma’s PADCEV in combination with KEYTRUDA for first-line treatment of radically unresectable urothelial carcinoma, offering a significant improvement over the current standard platinum-containing chemotherapy. The approval, which is the first of its kind in Japan, was based on a trial that showed nearly doubled median overall survival and significant extension of progression-free survival. The combination therapy has also been approved by the European Commission and the U.S. FDA for similar indications.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.